Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

DURHAM, N.C. - The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center.

Read the whole article on Science Blog

More from Science Blog